<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193621</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0692</org_study_id>
    <nct_id>NCT01193621</nct_id>
  </id_info>
  <brief_title>Early Clinical Evaluation of the Pharmacokinetics and Mechanism Based Pharmacodynamics of Haloperidol Using Positron Emission Tomography in Healthy Volunteers</brief_title>
  <official_title>Early Clinical Evaluation of the Pharmacokinetics and Mechanism Based Pharmacodynamics of Haloperidol Using Positron Emission Tomography in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study, the investigators will establish the clinical trial technology for&#xD;
      early evaluation of drug characteristics in terms of pharmacokinetics and pharmacodynamics&#xD;
      for haloperidol as a model drug, using positron emission tomography.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Study Design&#xD;
&#xD;
           This study will consist of two parts. One is &quot;biodistribution study of haloperidol&quot; in&#xD;
           12 subjects, and the other is &quot;receptor occupancy study of haloperidol&quot; in 12 subjects.&#xD;
           In the biodistribution study, 18F-haloperidol (10 mCi) will be injected intravenously&#xD;
           two times into each of the 12 subjects (cross-over design). Whole body PET will be&#xD;
           conducted after the first haloperidol injection and local brain PET after the 2nd&#xD;
           haloperidol injection after the 7 day washout period.&#xD;
&#xD;
           1.1 D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4&#xD;
&#xD;
        2. Measurement 2.1 The D2 receptor Occupancy of haloperidol.&#xD;
&#xD;
        3. Test schedule 3.1 Biodistribution study&#xD;
&#xD;
             -  Whole body PET (day 1)&#xD;
&#xD;
             -  Brain local PET (day 8) 3.2 Receptor occupancy study&#xD;
&#xD;
             -  Baseline PET before drug administration (day 1 0h), 6h (day 1 6h), 24h (day 2 0h),&#xD;
                after the first haloperidol administration (day 1 0h), and 24 h (day 8), 72 h (day&#xD;
                10), and 168 h (day 14) after the last dosing of haloperidol (day 7 0h).&#xD;
&#xD;
             -  Drug administration from day 1 through day 7 every 24 hours PK blood sampling (6&#xD;
                ml, each) prior to the first haloperidol administration (day 1 0h) and 6h (1 day&#xD;
                6h), 24h (2 day 0h), 48 h (3 day 0h), 96 h (5 day 0h), 144 h (7 day 0h) and, 0.5,&#xD;
                1, 2, 4, 6, 8, 12, 24 h (8day 0h), 48h (9day 0h), 72h (10 day 0h) after taking the&#xD;
                last oral dose of haloperidol&#xD;
&#xD;
        4. Analytic Methods 4.1 Pharmacokinetics: Noncompartmental Analysis Using Winnonlin&#xD;
           Compartment model using NONMEM VII 4.2 Pharmacodynamics in the brain: Emax or linear&#xD;
           model using NONMEM VII&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma haloperidol concentration</measure>
    <time_frame>day 1 0h (predose), day 1 6h, day 2 0h, day 3 0h (predose), day 5 0h (predose), and day 7 0h (predose), 0.5, 1, 2, 4, 6, 8, 12, 24(day 8 0h), 48(day 9 0h), 72h (day 10h)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>haloperidol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5, 1, 3 mg of haloperidol will be administered orally every 24 hours for 7 days to 4 healthy subjects in each dose level (a total of 12 subjects).&#xD;
Dose groups are as follows; D2-receptor occupancy study Group Single Oral Dose No. of subjects&#xD;
0.5 mg 4&#xD;
1 mg 4&#xD;
5 mg 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol, PET</intervention_name>
    <description>Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan&#xD;
D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4&#xD;
above doses will be administrated orally every 24 hours for 7 days.</description>
    <arm_group_label>haloperidol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy males as determined by medical history and physical examination&#xD;
&#xD;
          -  Age from 19 to 45 years&#xD;
&#xD;
          -  Weight ≥ 45 kg and within ± 20% of IBW&#xD;
&#xD;
          -  Clinical laboratory test results within normal reference range for the National Cancer&#xD;
             Center, Hospital or results with minor deviations which are judged to be not&#xD;
             clinically significant by the investigator&#xD;
&#xD;
          -  Normal blood pressure and heart rate (supine and standing) as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Are reliable and willing to make themselves available for the duration of the study,&#xD;
             and who will abide by the study restrictions&#xD;
&#xD;
          -  Have given written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,&#xD;
             neurological disorders capable of altering the absorption, metabolism or elimination&#xD;
             of drugs, or of constituting a risk factor when taking the study medication&#xD;
&#xD;
          -  An episode of febrile disease or infectious disease within the past 2 weeks&#xD;
&#xD;
          -  Evidence of significant active hematologic disease and/or blood donation in the last 2&#xD;
             months&#xD;
&#xD;
          -  Evidence of significant active neuropsychiatric disease&#xD;
&#xD;
          -  Regular use of drugs or abuse&#xD;
&#xD;
          -  History of drug hypersensitivity or clinically significant allergic reactions of any&#xD;
             origin&#xD;
&#xD;
          -  Participation in a study involving administration of an investigational compound&#xD;
             within the past 30 days&#xD;
&#xD;
          -  Have a regular alcohol intake greater than 21 units/week or subjects unwilling to stop&#xD;
             alcohol for the duration of the study periods&#xD;
&#xD;
          -  Intend to use concomitant drug therapy, including non prescription medication on a&#xD;
             regular basis apart from vitamin/mineral supplements&#xD;
&#xD;
          -  Smoking history for recent 3 months&#xD;
&#xD;
          -  Use of medication within 7 days prior to the study. If this situation arises inclusion&#xD;
             of an otherwise suitable volunteer may be at the discretion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>July 10, 2013</last_update_submitted>
  <last_update_submitted_qc>July 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Kyun-Seop Bae</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>early evaluation</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>Biodistribution</keyword>
  <keyword>D2-receptor occupancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

